Navigation Links
ChemoCentryx Announces Pricing of Initial Public Offering
Date:2/8/2012

MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the pricing of its initial public offering of 4,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by ChemoCentryx. In addition, the underwriters have a 30-day option to purchase up to an additional 675,000 shares of common stock from ChemoCentryx to cover over-allotments, if any.

Shares of ChemoCentryx's common stock will trade on the NASDAQ Global Select Market under the symbol "CCXI" beginning on February 8, 2012. The offering is expected to close on February 13, 2012, subject to customary closing conditions.

J.P. Morgan Securities LLC and Citigroup are acting as joint book-running managers of the offering, and Cowen and Company, LLC is acting as co-manager of the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 8, 2012. This offering is being made only by means of a prospectus, copies of which may be obtained from J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by phone at 866-803-9204, or from Citigroup, Attn: Prospectus Delivery Department, Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220 or by phone at 718-765-6732.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About ChemoCentryx 

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the c
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
2. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
3. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
4. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
5. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
9. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
10. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
11. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds ... Potassium Nitrate Industry" and "2014 Deep Research Report ... reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Amar Singh , Chief Business Officer and Executive Vice ... causes on July 30. "Sorrento is deeply saddened ... colleague. Our immediate thoughts go to Amar,s family and friends," ... Executive Officer. Mr. Singh joined Sorrento in ...
(Date:7/31/2014)...  ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2014.  Revenue for the quarter was $415.2 ... (a 1 percent decrease on a constant currency basis). Net ... to the quarter ended June 30, 2013. Diluted earnings per ... percent compared to the quarter ended June 30, 2013.  ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... Jan. 9, 2012    Lehigh Valley Technologies, Inc. (LVT) ... recently completed inspection by the U.S. Food and ... completed an onsite inspection with no Form 483 ... were no negative observations relating to cGMP (current ...
... Inc.,s ability to craft the pessary balloons that enhance ... commitment to premium quality output and complete mastery of ... Today,s pessaries are precision-manufactured medical devices that provide pelvic ... variety of gynecologic conditions, including prolapse. In years past, ...
Cached Medicine Technology:MedPlast's Pessary Balloon Manufacture Showcases Multi-Function Technical Mastery 2
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... J. Jill Suitor, PhD, of Purdue University as ... to Gerontology Award. , This distinguished honor is ... have helped bring about a new synthesis and ... designs addressing a significant problem in the literature. ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Sean P. Curran, PhD, of ... of the Nathan Shock New Investigator Award. , This ... knowledge about aging through basic biological research. It was ... founding member of GSA and pioneer in gerontological research ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Carole B. Lewis, PT, DPT, ... recipient of the Excellence in Rehabilitation of Aging Persons ... acknowledge outstanding contributions in the field of rehabilitation. The ... or patient care, or publications that may include scholarly ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new blog post explaining ... high cholesterol levels. , Clients who have a ... medical exam life insurance. These plans offer a convenient ... Since there are no medical examinations involved, clients who ... a few minutes. However, this convenience comes at a ...
(Date:8/1/2014)... August 01, 2014 Chilton Medical ... that aims to empower patients and their families ... health care by providing easy, secure access to ... patients instant, web-based access to their health information ... results, medications, allergies, demographic information, visit history, discharge/aftercare ...
Breaking Medicine News(10 mins):Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Chilton Medical Center Launches Online Patient Portal 2
... new project is an interdisciplinary research project covering ... has been awarded EUR 6 million from the ... The project will gather scientists from seven countries, ... University of Gothenburg, Sweden. , Those working on ...
... In the rat race of life, one thing is certain: ... in Molecular Ecology finds the same is true ... most form distinct neighborhoods where they spend the majority of ... lively neighborhoods each with its own personality. But scientists ...
... by Erich Lindemann Community Mental Health Education Center Initiative ... of Professional Psychology BOSTON, May 26 "The ... the needs of 1.5 million soldiers and marines and ... Estimates are as high as 33% that these ...
... connect using technology powered by 100 percent ... N.Y., May 26 Optimum Lightpath, a ... New York metropolitan area businesses, today introduced ... available exclusively through Optimum Lightpath to New ...
... Novel Oral Therapies Will Garner 29 Percent of the ... from Decision ResourcesWALTHAM, Mass., May 26 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the approval ... as the increasing use of current and emerging injectable ...
... helps explain association between the two illnesses , , TUESDAY, ... gum disease (periodontitis) and heart disease has been discovered ... coronary heart disease (CHD) has been known for years, ... confirmed. The University of Kiel team found that the ...
Cached Medicine News:Health News:Sahlgrenska Academy to lead major European project on obesity 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 4Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 2Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 3Health News:Gum Disease, Heart Disease Share Genetic Link 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: